Chronic Myeloid Leukemia Coverage from Every Angle

Published Medical Literature

Are Genetic Variants and Plasma Imatinib Levels Linked to Improved Outcomes in CML?
Second-Generation TKIs for CML: Weighing Clinical Benefits and Cost
Willingness to Discontinue TKI Treatment of CML: Findings From Survey of Patients
Ventricular Fibrillation and Direct ABL Kinase Inhibition in CML: Case Study
Diabetes Mellitus After Nilotinib Treatment for CML: Case Study
Generic Imatinib for CML: Experience From Eastern India
Is Switching TKIs Effective in Achieving Clinical Response in Chronic-Phase CML?
Treatment-Free Remission in CML: An Outcome for All Patients?
Flumatinib Versus Imatinib for Chronic-Phase CML: Phase III FESTnd Trial
Can CRISPR-Knockout Screening Identify Drug Resistance Targets in CML?
Neutrophil Migration Analysis in Atypical CML: Case Study
Case Study in CML: Is Imatinib Treatment Safe During Breastfeeding?
Adding Ropeginterferon Alpha‐2b to Imatinib for Chronic-Phase CML
Accelerated-Phase CML: Is Dasatinib Plus Decitabine Active?
Comorbidities at Diagnosis: Predictive of Outcomes in CML?
Late Molecular Recurrence and Treatment-Free Remission in CML
Does BCR-ABL Transcript Subtype Affect Response to Nilotinib in CML?
Nilotinib for CML With Co-expression of e13a2 and e14a2 Transcripts
Fatigue in Patients With CML: Focus on Physical Activity
Comparing Prognostic Scores in Predicting Outcomes in CML
Is Low-Dose Ponatinib of Benefit in CML After Intolerance to Other Treatments?
Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?
Impact of Low-Dose Versus Full-Dose TKIs on CML Remission
Erythropoietin Therapy for Patients With CML Who Have Late Anemia
Is Low-Dose Ponatinib of Benefit in CML After Intolerance to Other Treatments?
Incidence of Imatinib-Induced Hypogammaglobulinemia in Children With CML
Chronic Phase CML Outcomes Update in the Era of Multiple TKIs
Predictive Biomarkers of Treatment-Free Remission in CML Under Study
Cardiovascular Risk With Ponatinib Treatment in CML: Focus on Lipid Profile
Trends in Primary Treatment and Survival Among Elderly Patients With CML
Is Molecular Response to Bosutinib or Imatinib Linked to Quality of Life in CML?
Effects of TKI Combinations on Drug Resistance in CML: Focus on Axitinib and Asciminib
Italian Study on Use of Second-Generation TKIs as Front-Line Therapies in CML
Self-Initiated Discontinuation of Nilotinib in CML: Case Report
CML and Cardiovascular Adverse Events After TKI Therapy: Identifying Probable Pathways
CML Pathology and the Quest for Effective Biomarkers
Korean Study Identifies Benefits of Combining Metformin With Nilotinib in CML
Latent Therapeutic Target for Mitigating Inflammation in CML Cells
Role of Long Noncoding RNA H19 in CML
Early Switch to Dasatinib After Suboptimal Response to Imatinib in Chronic Phase CML
Potential Mechanism of Ponatinib-Induced Vascular Toxicity in CML
Case Report of Aggressive Atypical Chronic Myeloid Leukemia
Nilotinib for CML: Case Report of Severe Valvular Aortic Stenosis
Identifying Commonalities Among CML Blast Crisis Cells
TKI Therapy and Donor Lymphocyte Infusion in Relapsed CML
First-Line Imatinib, Dasatinib, and Nilotinib in CML: Comparing Safety and Costs
Anticancer Potential of Tetrahydrobenzimidazole Derivative in CML
Long-Term Efficacy of Nilotinib in Chronic Phase CML
Next-Generation Sequencing for Mutation Testing in CML: Position Paper
Identifying a Tumor Suppressor in Chronic Myeloid Leukemia
Proposed Guidelines for CML Treatment: Treatment-Free Remission Is the Goal
Early Research on Asciminib Plus Ponatinib in Resistant CML
Ponatinib and Chemotherapy for Blast Phase Chronic Myeloid Leukemia
Health-Related Quality of Life in Patients Receiving TKI Therapy for CML
Novel Strategy for Treating CML: Repurpose Existing Anticancer Agents
CML Case Study: Neurologic Symptoms Related to Use of Nilotinib?
Strategy for Overcoming BCR-ABL1T315I–Positive Clones in Resistant CML
Study Finds Asciminib Active in Heavily Pretreated Patients With CML
Identifying Pathologic Characteristics of NKT-Like Cells in Patients Treated for CML
Study Finds Complex BCR-ABL1 Signal Patterns Linked to Poorer Prognosis in CML
Nilotinib Dosing in Pediatric Patients With CML
Treatment-Free Remission and Dasatinib Discontinuation for Chronic Phase CML
The Bone Marrow Niche in Treatment-Resistant CML: A Review
Advances in Molecular Tools for Monitoring CML
Health-Related Quality-of-Life Outcomes With TKI Therapy in Newly Diagnosed CML
Cognitive Behavioral Therapy via FaceTime for TKI-Related Fatigue in CML
Meta-analysis Compares Front-Line Treatments in Newly Diagnosed Chronic-Phase CML
Using BCR-ABL1 Doubling and Halving Times to Predict Patient Responses in CML
How SOX30 Methylation May Impact Progression of CML
Targeting Leukemic Stem Cells in CML With Immunotherapy
Comparing Front-Line Treatments of Newly Diagnosed Chronic Phase CML
Nilotinib Treatment for Rare CML Fusion Transcript: Case Study
German Population–Based Study Offers Insight Into Use of TKIs for CML
Arsenic Sulfide Nanoformulation and CML Cells
Interaction of BCR-ABL and Beclin-1 in CML
Can Drug Rotation Therapy Delay Resistance to Treatment in CML?
Role of FAM168A Protein in Proliferation of CML Cells
First-Line Imatinib Dosing in Elderly Patients With CML
Evaluating Outcomes for Children With Advanced Phase of CML at Time of Diagnosis
Tyrosine Kinase Inhibitor Rotation Therapy in CML
Axis of Power in Tyrosine Kinase Inhibitor–Resistant CML
CRISPR-Based System Under Study in Resistant CML
Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?
Molecular Relapse in CML After TKI Discontinuation
Ten-Year Outcomes With Imatinib Treatment in CML
Review of Potential Therapeutic Options for Drug-Resistant CML
Impact of Health-Care Costs in CML on an Oncology Care Model
Does NUMB Protein Play a Role in Imatinib-Resistant CML?
Does Inhibition of Tumor Necrosis Factor Alpha Affect Tumor Growth in CML?
Role for RNA-Binding Protein in Progression of CML
ENESTnext Trial: Evaluating Molecular Response With Front-Line Nilotinib in CML
Genetic Polymorphism and CML Risk
Shedding Light on Treatment-Resistant Leukemia Stem Cells
Imatinib Discontinuation Among Pediatric Patients With CML
IFN-α in CML: Mediator of CML Stem Cell Exhaustion Identified
Dasatinib in CML: Activating Natural Killer Cells
Review Finds Real-World Studies May Benefit CML Research
Research Sheds Light on Plasmacytoid Dendritic Cells in CML
Mitigating Adverse Events With Bosutinib Treatment in CML
Timely Molecular Monitoring of Patients With CML
Therapeutic Response in de Novo vs. Therapy-Related CML
Conception and Pregnancy in Patients Treated With TKIs for CML
Case of CML Relapse Decades After Stem Cell Transplant
Insights From Observational Study of 1,000+ Patients With CML
Impact of Donor Clonal Hematopoiesis on Stem Cell Transplantation
Rare Case of Autoimmune Hemolytic Anemia in a Patient With CML
Coexistence of CML and Multiple Myeloma: A Case Study
Case Study Highlights Complexities of Cesarean Section in Patient With CML
Can Tyrosine Kinase Inhibitors for CML Affect PSA Titers Unrelated to Prostatic Disease?
Preexisting Drug Resistance in Philadelphia-Positive Leukemias
Analysis of Bone Marrow Stromal Cells in Patients With CML During Chemotherapy
Study Offers Further Support to Long-Term Treatment-Free Remission in CML
TKI Therapy and Its Influence on Quality of Life in Patients With CML
Is Bone Marrow Core Biopsy Always Necessary in Initial Evaluation for CML?
Guidelines for Managing Clostridium Difficile Infection in Younger Transplant Recipients
End-of-Life Care After Allogeneic Hematopoietic Cell Transplantation
Are Patients Treated for Breast Cancer at Increased Risk of CML?
Long-Term Outcomes With Dasatinib in CML in Accelerated Phase
Clinical and Economic Impact of Early Versus Late Molecular Monitoring in CML
Update on Reduced-Intensity Conditioning for Certain Hematologic Malignancies
Investigating Pleural Effusion Associated With Dasatinib Therapy in CML
Long-Term Results With Bosutinib in Chronic-Phase CML
Closer Look at Contribution of Oncogenes to Development of CML
Genetic Susceptibility to Myeloid Malignancies
Attitudes of Patients With CML Toward Treatment-Free Remission
Shedding Light on Imatinib Resistance in CML: Focus on T315I Mutation
Simulation Study Evaluates Dose Reduction of Tyrosine Kinase Inhibitors in CML
Do Tyrosine Kinase Inhibitors Affect Thrombopoietin Levels in Patients With CML?
Treating CML in Pediatric Patients: Is Imatinib Safe and Effective?
Navigating Pregnancy and Tyrosine Kinase Inhibitor Therapy in Women With CML
Is CML Becoming More Prevalent in France?
Patient-Centered Approach to Treatment-Free Remission in CML
Lower Dose of Dasatinib in Newly Diagnosed CML
Managing Side Effects of Bosutinib in Patients With Ph-Positive CML
EURO-SKI Trial: Discontinuation of Tyrosine Kinase Inhibitor Therapy in CML
Switching to Lower Dose of Nilotinib for TKI-Intolerant Patients With CML
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia
Cardiovascular Health Considerations When Using Tyrosine Kinase Inhibitors
How Common Is Cognitive Impairment Among Older Patients With Blood Cancers?
BFORE Trial: Bosutinib Versus Imatinib in Newly Diagnosed CML
Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
Review of Tyrosine Kinase Inhibitor Use in Chronic Myeloid Leukemia
Predicting Response to Therapy With TKIs in Patients With Chronic Myeloid Leukemia
Dasatinib Dosing: Balance Between Efficacy and Toxicity
Long-Term Bosutinib Treatment for CML and Health-Related Quality of Life
CML Study IV: 10-Year Survival Results With First-Line Imatinib Treatment
Guidelines for Use of Growth Factors in CML and Other Leukemias

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.